(AZE) Azelis - Ratings and Ratios
Chemicals, Food, Ingredients, Additives, Materials
AZE EPS (Earnings per Share)
AZE Revenue
Description: AZE Azelis
Azelis Group NV is a leading distributor of specialty chemicals and food ingredients, catering to diverse industries such as life sciences, industrial chemicals, and more. The companys extensive product portfolio and global presence across Europe, Middle East, Africa, the Americas, and Asia-Pacific make it a significant player in the specialty chemicals sector.
From a business perspective, Azelis revenue streams are diversified across various end-markets, including personal care, pharmaceuticals, food and nutrition, and industrial applications. This diversification can help mitigate risks associated with market fluctuations. To further analyze the companys performance, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin can be examined. For instance, a stable or increasing gross margin could indicate effective pricing strategies and supply chain management.
In terms of valuation, Azelis P/E ratio of 18.77 suggests that the stock is trading at a reasonable multiple relative to its earnings. Additionally, the forward P/E ratio of 18.21 implies that analysts expect earnings to grow, potentially driving the stock price higher. Return on Equity (RoE) of 11.15% indicates that the company is generating decent returns for its shareholders. To gain a deeper understanding, metrics such as Debt-to-Equity ratio and Interest Coverage ratio can be analyzed to assess Azelis financial health and leverage.
To evaluate Azelis stock performance, trends in its market capitalization, trading volume, and short interest can be monitored. A rising market capitalization can indicate increasing investor confidence, while a high short interest may suggest potential downside risks. By combining these insights with technical analysis, a more comprehensive view of Azelis stock can be formed, helping to identify potential trading opportunities.
AZE Stock Overview
| Market Cap in USD | 3,759m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
AZE Stock Ratings
| Growth Rating | -76.2% |
| Fundamental | 71.4% |
| Dividend Rating | 50.1% |
| Return 12m vs S&P 500 | -42.0% |
| Analyst Rating | - |
AZE Dividends
| Dividend Yield 12m | 1.50% |
| Yield on Cost 5y | 0.86% |
| Annual Growth 5y | 57.79% |
| Payout Consistency | 93.8% |
| Payout Ratio | 25.6% |
AZE Growth Ratios
| Growth Correlation 3m | -28% |
| Growth Correlation 12m | -79.7% |
| Growth Correlation 5y | -76.5% |
| CAGR 5y | -16.87% |
| CAGR/Max DD 5y | -0.32 |
| Sharpe Ratio 12m | -0.52 |
| Alpha | -43.53 |
| Beta | 0.614 |
| Volatility | 31.80% |
| Current Volume | 305.5k |
| Average Volume 20d | 282.4k |
| Stop Loss | 12.3 (-3.5%) |
| Signal | -2.23 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (302.4m TTM) > 0 and > 6% of Revenue (6% = 437.9m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -2.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.47% (prev 10.36%; Δ 0.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 590.7m > Net Income 302.4m (YES >=105%, WARN >=100%) |
| Net Debt (1.54b) to EBITDA (869.6m) ratio: 1.77 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (244.0m) change vs 12m ago -0.08% (target <= -2.0% for YES) |
| Gross Margin 17.72% (prev 19.85%; Δ -2.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 128.8% (prev 113.2%; Δ 15.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.42 (EBITDA TTM 869.6m / Interest Expense TTM 278.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.66
| (A) 0.13 = (Total Current Assets 1.58b - Total Current Liabilities 818.9m) / Total Assets 5.76b |
| (B) 0.15 = Retained Earnings (Balance) 876.3m / Total Assets 5.76b |
| (C) 0.12 = EBIT TTM 673.9m / Avg Total Assets 5.67b |
| (D) 2.38 = Book Value of Equity 6.76b / Total Liabilities 2.84b |
| Total Rating: 4.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.39
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 12.18% = 5.0 |
| 3. FCF Margin 7.73% = 1.93 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 1.97 = 0.07 |
| 6. ROIC - WACC 4.92% = 6.16 |
| 7. RoE 11.15% = 0.93 |
| 8. Rev. Trend 27.48% = 1.37 |
| 9. Rev. CAGR 11.91% = 1.49 |
| 10. EPS Trend 4.43% = 0.11 |
| 11. EPS CAGR 56.99% = 2.50 |
What is the price of AZE shares?
Over the past week, the price has changed by -5.49%, over one month by -10.78%, over three months by -12.58% and over the past year by -32.17%.
Is Azelis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZE is around 10.41 EUR . This means that AZE is currently overvalued and has a potential downside of -18.29%.
Is AZE a buy, sell or hold?
What are the forecasts/targets for the AZE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.6 | 53.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 11.4 | -10.6% |
AZE Fundamental Data Overview
Market Cap EUR = 3.23b (3.23b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 304.5m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 19.0435
P/E Forward = 20.3666
P/S = 0.7635
P/B = 1.2332
Beta = 0.571
Revenue TTM = 7.30b EUR
EBIT TTM = 673.9m EUR
EBITDA TTM = 869.6m EUR
Long Term Debt = 1.61b EUR (from longTermDebt, last quarter)
Short Term Debt = 95.6m EUR (from shortTermDebt, last quarter)
Debt = 1.71b EUR (Calculated: Short Term 95.6m + Long Term 1.61b)
Net Debt = 1.54b EUR (from netDebt column, last quarter)
Enterprise Value = 4.63b EUR (3.23b + Debt 1.71b - CCE 304.5m)
Interest Coverage Ratio = 2.42 (Ebit TTM 673.9m / Interest Expense TTM 278.0m)
FCF Yield = 12.18% (FCF TTM 564.3m / Enterprise Value 4.63b)
FCF Margin = 7.73% (FCF TTM 564.3m / Revenue TTM 7.30b)
Net Margin = 4.14% (Net Income TTM 302.4m / Revenue TTM 7.30b)
Gross Margin = 17.72% ((Revenue TTM 7.30b - Cost of Revenue TTM 6.00b) / Revenue TTM)
Tobins Q-Ratio = 0.69 (Enterprise Value 4.63b / Book Value Of Equity 6.76b)
Interest Expense / Debt = 4.18% (Interest Expense 71.5m / Debt 1.71b)
Taxrate = 26.02% (from yearly Income Tax Expense: 66.6m / 256.1m)
NOPAT = 498.6m (EBIT 673.9m * (1 - 26.02%))
Current Ratio = 1.93 (Total Current Assets 1.58b / Total Current Liabilities 818.9m)
Debt / Equity = 0.59 (Debt 1.71b / last Quarter total Stockholder Equity 2.88b)
Debt / EBITDA = 1.97 (Net Debt 1.54b / EBITDA 869.6m)
Debt / FCF = 3.03 (Debt 1.71b / FCF TTM 564.3m)
Total Stockholder Equity = 2.71b (last 4 quarters mean)
RoA = 5.25% (Net Income 302.4m, Total Assets 5.76b )
RoE = 11.15% (Net Income TTM 302.4m / Total Stockholder Equity 2.71b)
RoCE = 15.58% (Ebit 673.9m / (Equity 2.71b + L.T.Debt 1.61b))
RoIC = 11.41% (NOPAT 498.6m / Invested Capital 4.37b)
WACC = 6.48% (E(3.23b)/V(4.94b) * Re(8.28%)) + (D(1.71b)/V(4.94b) * Rd(4.18%) * (1-Tc(0.26)))
Shares Correlation 5-Years: 56.40 | Cagr: 1.07%
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 80.68% ; FCFE base≈604.5m ; Y1≈745.8m ; Y5≈1.27b
Fair Price DCF = 84.90 (DCF Value 20.67b / Shares Outstanding 243.5m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 27.48 | Revenue CAGR: 11.91%
Rev Growth-of-Growth: 10.32
EPS Correlation: 4.43 | EPS CAGR: 56.99%
EPS Growth-of-Growth: -38.49